top of page
Search

Tied for 1st in subchallenge

  • Writer: Russell Greiner
    Russell Greiner
  • Jul 28, 2017
  • 1 min read

Updated: May 7, 2018

At the Prostate Cancer DREAM Challenge.


Over 50 teams, from around the world, competed in the Prostate Cancer DREAM Challenge, to predict the survival and toxicity of docetaxel treatment in patients with metastatic castrate resistant prostate cancer. Our team, PC LEARN, tied for 1st in one of the 2 specific subchallenges -- see here.


See the press release (we are "Canada" and "Israel"); and the article.


Recent Posts

See All

Commenti

bottom of page